BioGaia Signs Agreement in Indonesia
Interbat is the seventh largest pharmaceutical company in Indonesia with 1 500 employees. Most of their business is manufacturing and sales of their own prescription and over the counter pharmaceuticals.
23 Mar 2010 --- BioGaia has signed an agreement with the Indonesian pharmaceutical company Interbat. The agreement refers to sales of BioGaia Probiotic drops in Indonesia under the BioGaia brand. Launch is estimated during the first quarter of 2011.
“We are very much looking forward to the cooperation with Interbat. The company has a strong local position and regularly visits paediatricians, who are the target group for our probiotic drops”, says Peter Rothschild, President, BioGaia AB.
Interbat is the seventh largest pharmaceutical company in Indonesia with 1 500 employees. Most of their business is manufacturing and sales of their own prescription and over the counter pharmaceuticals. The representatives from Interbat regularly visit some 30 000 medical doctors in Indonesia and Interbat is represented in 1 200 of Indonesian hospitals. Of the 900 Interbat representatives around 700 will sell the BioGaia Probiotic drops.
Indonesia has 230 million inhabitants and the knowledge of probiotics is fairly high among the general public. The potential for the market is therefore estimated as large despite the relatively low level of income in the country. BioGaia Probiotic tablets are already on the market in Indonesia through the pharmaceutical company Kalbe Farma.
